These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 28755394

  • 1. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
    Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B.
    Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
    [Abstract] [Full Text] [Related]

  • 2. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A, Lacour JP, Fowler JF, Weinberg JM, Gospodinov D, Schuck E, Jauch-Lembach J, Balfour A, Leonardi CL.
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [Abstract] [Full Text] [Related]

  • 3. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ.
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [Abstract] [Full Text] [Related]

  • 4. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
    Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B.
    J Am Acad Dermatol; 2017 Jun; 76(6):1093-1102. PubMed ID: 28291552
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
    Cai L, Li L, Cheng H, Ding Y, Biao Z, Zhang S, Geng S, Liu Q, Fang H, Song Z, Lu Y, Li S, Guo Q, Tao J, He L, Gu J, Yang Q, Han X, Gao X, Deng D, Li S, Wang Q, Zhu J, Zhang J.
    Adv Ther; 2022 Jan; 39(1):583-597. PubMed ID: 34816373
    [Abstract] [Full Text] [Related]

  • 6. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
    Gerdes S, Thaçi D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, Afonso M, Woehling H.
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
    Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, Pablos JL, Rizzo W, Hrycaj P, Zhang N, Shergy W, Kaur P.
    Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
    [Abstract] [Full Text] [Related]

  • 9. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
    Griffiths CEM, Thaçi D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J, EGALITY study group, Hattebuhr N, Poetzl J, Woehling H, Wuerth G, Afonso M.
    Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
    [Abstract] [Full Text] [Related]

  • 10. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.
    Samtsov AV, Bakulev AL, Khairutdinov VR, Kokhan MM, Korotaeva TV, Minullin IK, Vylegzhanina OA, Dubenskiy VV, Khalilov BV, Khotko AA, Zykova OS, Chumachenko IV, Lukyanov AM, Artemeva AV, Pukhtinskaia PP.
    PLoS One; 2022 Apr; 17(2):e0263214. PubMed ID: 35130291
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
    Feldman SR, Reznichenko N, Pulka G, Kingo K, George Galdava, Berti F, Sobierska J, Dias R, Guenzi E, Hendrik Otto, Haliduola HN, Kay R, Stroissnig H.
    BioDrugs; 2021 Nov; 35(6):735-748. PubMed ID: 34657274
    [Abstract] [Full Text] [Related]

  • 13. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
    Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld KH, Schaible J, McCabe D.
    Am J Clin Dermatol; 2022 Sep; 23(5):719-728. PubMed ID: 35934770
    [Abstract] [Full Text] [Related]

  • 14. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
    Menter A, Arenberger P, Balser S, Beissert S, Cauthen A, Czeloth N, Soung J, Jazayeri S, Weisenseel P, Jayadeva G.
    Expert Opin Biol Ther; 2021 Jan; 21(1):87-96. PubMed ID: 33317345
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
    Markus R, McBride HJ, Ramchandani M, Chow V, Liu J, Mytych D, Fanjiang G.
    Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
    [Abstract] [Full Text] [Related]

  • 17. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
    Gniadecki R, Leonardi CL, Gordon KB, Gu Y, Geng Z, Nader A, Teixeira HD.
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1297-1304. PubMed ID: 29524255
    [Abstract] [Full Text] [Related]

  • 18. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
    Cohen S, Pablos JL, Pavelka K, Müller GA, Matsumoto A, Kivitz A, Wang H, Krishnan E.
    Arthritis Res Ther; 2019 Mar 29; 21(1):84. PubMed ID: 30922373
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.
    Bagel J, Tyring S, Rice KC, Collier DH, Kricorian G, Chung J, Iles J, Stolshek BS, Kaliyaperumal A, Papp KA.
    Br J Dermatol; 2017 Aug 29; 177(2):411-418. PubMed ID: 28196270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.